398 related articles for article (PubMed ID: 28133797)
1. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
Moore PL; Gorman J; Doria-Rose NA; Morris L
Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
[TBL] [Abstract][Full Text] [Related]
2. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
[TBL] [Abstract][Full Text] [Related]
3. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
4. Complementary Roles of Antibody Heavy and Light Chain Somatic Hypermutation in Conferring Breadth and Potency to the HIV-1-Specific CAP256-VRC26 bNAb Lineage.
Sacks D; Wiehe K; Morris L; Moore PL
J Virol; 2022 May; 96(10):e0027022. PubMed ID: 35510865
[TBL] [Abstract][Full Text] [Related]
5. Identification and specificity of broadly neutralizing antibodies against HIV.
McCoy LE; Burton DR
Immunol Rev; 2017 Jan; 275(1):11-20. PubMed ID: 28133814
[TBL] [Abstract][Full Text] [Related]
6. Human immunoglobulin repertoire analysis guides design of vaccine priming immunogens targeting HIV V2-apex broadly neutralizing antibody precursors.
Willis JR; Berndsen ZT; Ma KM; Steichen JM; Schiffner T; Landais E; Liguori A; Kalyuzhniy O; Allen JD; Baboo S; Omorodion O; Diedrich JK; Hu X; Georgeson E; Phelps N; Eskandarzadeh S; Groschel B; Kubitz M; Adachi Y; Mullin TM; Alavi NB; Falcone S; Himansu S; Carfi A; Wilson IA; Yates JR; Paulson JC; Crispin M; Ward AB; Schief WR
Immunity; 2022 Nov; 55(11):2149-2167.e9. PubMed ID: 36179689
[TBL] [Abstract][Full Text] [Related]
7. A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.
Bibollet-Ruche F; Russell RM; Ding W; Liu W; Li Y; Wagh K; Wrapp D; Habib R; Skelly AN; Roark RS; Sherrill-Mix S; Wang S; Rando J; Lindemuth E; Cruickshank K; Park Y; Baum R; Carey JW; Connell AJ; Li H; Giorgi EE; Song GS; Ding S; Finzi A; Newman A; Hernandez GE; Machiele E; Cain DW; Mansouri K; Lewis MG; Montefiori DC; Wiehe KJ; Alam SM; Teng IT; Kwong PD; Andrabi R; Verkoczy L; Burton DR; Korber BT; Saunders KO; Haynes BF; Edwards RJ; Shaw GM; Hahn BH
mBio; 2023 Feb; 14(1):e0337022. PubMed ID: 36629414
[TBL] [Abstract][Full Text] [Related]
8. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
10. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
11. Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.
Andrabi R; Voss JE; Liang CH; Briney B; McCoy LE; Wu CY; Wong CH; Poignard P; Burton DR
Immunity; 2015 Nov; 43(5):959-73. PubMed ID: 26588781
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
13. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
McGuire AT
Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
[TBL] [Abstract][Full Text] [Related]
14. Strategies for a multi-stage neutralizing antibody-based HIV vaccine.
Andrabi R; Bhiman JN; Burton DR
Curr Opin Immunol; 2018 Aug; 53():143-151. PubMed ID: 29775847
[TBL] [Abstract][Full Text] [Related]
15. Membrane-bound mRNA immunogens lower the threshold to activate HIV Env V2 apex-directed broadly neutralizing B cell precursors in humanized mice.
Melzi E; Willis JR; Ma KM; Lin YC; Kratochvil S; Berndsen ZT; Landais EA; Kalyuzhniy O; Nair U; Warner J; Steichen JM; Kalyuzhniy A; Le A; Pecetta S; Perez M; Kirsch K; Weldon SR; Falcone S; Himansu S; Carfi A; Sok D; Ward AB; Schief WR; Batista FD
Immunity; 2022 Nov; 55(11):2168-2186.e6. PubMed ID: 36179690
[TBL] [Abstract][Full Text] [Related]
16. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth.
Chen X; Zhou T; Schmidt SD; Duan H; Cheng C; Chuang GY; Gu Y; Louder MK; Lin BC; Shen CH; Sheng Z; Zheng MX; Doria-Rose NA; Joyce MG; Shapiro L; Tian M; Alt FW; Kwong PD; Mascola JR
Immunity; 2021 Feb; 54(2):324-339.e8. PubMed ID: 33453152
[TBL] [Abstract][Full Text] [Related]
17. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Landais E; Moore PL
Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
[TBL] [Abstract][Full Text] [Related]
19. Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
Zhang R; Verkoczy L; Wiehe K; Munir Alam S; Nicely NI; Santra S; Bradley T; Pemble CW; Zhang J; Gao F; Montefiori DC; Bouton-Verville H; Kelsoe G; Larimore K; Greenberg PD; Parks R; Foulger A; Peel JN; Luo K; Lu X; Trama AM; Vandergrift N; Tomaras GD; Kepler TB; Moody MA; Liao HX; Haynes BF
Sci Transl Med; 2016 Apr; 8(336):336ra62. PubMed ID: 27122615
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
Kwong PD; Mascola JR
Immunity; 2018 May; 48(5):855-871. PubMed ID: 29768174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
